Breakthrough in targeted therapy for non-small cell lung cancer

Zhencong Ye; Yongmei Huang; Jianhao Ke; Xiao Zhu; Shuilong Leng; Hui Luo

doi:10.1016/j.biopha.2020.111079

Breakthrough in targeted therapy for non-small cell lung cancer

Biomed Pharmacother. 2021 Jan:133:111079. doi: 10.1016/j.biopha.2020.111079. Epub 2020 Dec 4.

Authors

Zhencong Ye¹, Yongmei Huang², Jianhao Ke³, Xiao Zhu⁴, Shuilong Leng⁵, Hui Luo⁶

Affiliations

¹ Southern Marine Science and Engineering Guangdong Laboratory (Zhanjiang), Zhanjiang, China; Guangdong Key Laboratory for Research and Development of Natural Drugs, The Marine Biomedical Research Institute, Guangdong Medical University, Zhanjiang, China.
² Southern Marine Science and Engineering Guangdong Laboratory (Zhanjiang), Zhanjiang, China; Guangdong Key Laboratory for Research and Development of Natural Drugs, The Marine Biomedical Research Institute, Guangdong Medical University, Zhanjiang, China; The Key Lab of Zhanjiang for R&D Marine Microbial Resources in the Beibu Gulf Rim, Guangdong Medical University, Zhanjiang, China; The Marine Biomedical Research Institute of Guangdong Zhanjiang, Zhanjiang, China.
³ College of Agriculture, South China Agricultural University, Guangzhou, China.
⁴ Southern Marine Science and Engineering Guangdong Laboratory (Zhanjiang), Zhanjiang, China; Guangdong Key Laboratory for Research and Development of Natural Drugs, The Marine Biomedical Research Institute, Guangdong Medical University, Zhanjiang, China; The Key Lab of Zhanjiang for R&D Marine Microbial Resources in the Beibu Gulf Rim, Guangdong Medical University, Zhanjiang, China; The Marine Biomedical Research Institute of Guangdong Zhanjiang, Zhanjiang, China. Electronic address: xzhu@gdmu.edu.cn.
⁵ Guangzhou Municipal and Guangdong Provincial Key Laboratory of Protein Modification and Degradation, School of Basic Medical Science, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou, China. Electronic address: shuilongleng@gzhmu.edu.cn.
⁶ Southern Marine Science and Engineering Guangdong Laboratory (Zhanjiang), Zhanjiang, China; Guangdong Key Laboratory for Research and Development of Natural Drugs, The Marine Biomedical Research Institute, Guangdong Medical University, Zhanjiang, China; The Key Lab of Zhanjiang for R&D Marine Microbial Resources in the Beibu Gulf Rim, Guangdong Medical University, Zhanjiang, China; The Marine Biomedical Research Institute of Guangdong Zhanjiang, Zhanjiang, China. Electronic address: luohui@gdmu.edu.cn.

PMID: 33378976
DOI: 10.1016/j.biopha.2020.111079

Abstract

Non-small cell lung cancer (NSCLC) remains by far the single most common malignancy of lung cancer which causes more and more mortality in recent years. NSCLC accounts for more than 80 % of lung cancers, and the vast majority of patients were found to be in advanced inoperable stages. Chemotherapy used to be the main treatment for NSCLC, but due to its obvious side effects. Chemotherapy gradually withdrew from the stage of history. In recent years, cellular and molecular biotechnology has developed rapidly, and researchers have begun to target key genes and regulatory molecules for treatment. Targeted drugs have also emerged. The purpose of this review is to introduce important research achievements in recent years and the treatment progress of new drugs.

Keywords: ALK; Chemotherapy; EGFR; Non-small cell lung cancer; Targeted therapy.

Publication types

Review

MeSH terms

Animals
Antineoplastic Agents / adverse effects
Antineoplastic Agents / therapeutic use*
Carcinoma, Non-Small-Cell Lung / drug therapy*
Carcinoma, Non-Small-Cell Lung / enzymology
Carcinoma, Non-Small-Cell Lung / pathology
Humans
Lung Neoplasms / drug therapy*
Lung Neoplasms / enzymology
Lung Neoplasms / pathology
Molecular Targeted Therapy
Precision Medicine
Protein Kinase Inhibitors / adverse effects
Protein Kinase Inhibitors / therapeutic use*
Protein-Tyrosine Kinases / antagonists & inhibitors*
Protein-Tyrosine Kinases / genetics
Protein-Tyrosine Kinases / metabolism
Proto-Oncogene Proteins p21(ras) / antagonists & inhibitors*
Proto-Oncogene Proteins p21(ras) / genetics
Proto-Oncogene Proteins p21(ras) / metabolism
Signal Transduction
Treatment Outcome

Substances

Antineoplastic Agents
KRAS protein, human
Protein Kinase Inhibitors
Protein-Tyrosine Kinases
Proto-Oncogene Proteins p21(ras)